Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP104 in Complement Inhibitor-naïve PNH
NCT05476887Phase 2Active, not recruiting
- Sponsor
- Kira Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of KP104 in paroxysmal nocturnal hemoglobinuria (PNH) (5 arms), sponsored by Kira Pharmaceuticals. Primary endpoints: Number of participants with Dose-limiting toxicities, Percentage of participants with >= 2 g/dL increase in hemoglobin level from Baseline in the absence of transfusion for weekly dosing at Week 12 and 2 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
KP104
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05476887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476887.